Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
icenticaftor - CFTR potentiator
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04072887 (CQBW251B2201)
Chronic obstructive pulmonary disease (COPD)
Phase 2
956
Trough FEV1 (Forced Expiratory Volume in 1 second) change from baseline after
12 weeks of treatment
QBW251 450 mg
QBW251 300 mg
QBW251 150 mg
QBW251 75 mg
QBW251 25 mg
Placebo
COPD patients on background triple inhaled therapy (LABA / LAMA / ICS)
Target Patients
Read-out Milestone(s)
Publication
2022
Primary publications planned for 2022
112 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation